These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 39049789)

  • 1. Thyroid hormone levels in children with Prader-Willi syndrome: a randomized controlled growth hormone trial and 10-year growth hormone study.
    Trueba-Timmermans DJ; Grootjen LN; Kerkhof GF; Rings EHHM; Hokken-Koelega ACS
    Eur J Endocrinol; 2024 Aug; 191(2):126-133. PubMed ID: 39049789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid hormone levels in children with Prader-Willi syndrome before and during growth hormone treatment.
    Festen DA; Visser TJ; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):449-56. PubMed ID: 17716335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid function from birth to adolescence in Prader-Willi syndrome.
    Sharkia M; Michaud S; Berthier MT; Giguère Y; Stewart L; Deladoëy J; Deal C; Van Vliet G; Chanoine JP
    J Pediatr; 2013 Sep; 163(3):800-5. PubMed ID: 23623517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central hypothyroidism improves with age in very young children with Prader-Willi syndrome.
    Konishi A; Ida S; Shoji Y; Etani Y; Kawai M
    Clin Endocrinol (Oxf); 2021 Mar; 94(3):384-391. PubMed ID: 32869320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of growth hormone treatment on thyroid function in pediatric patients with Prader-Willi syndrome.
    Oto Y; Murakami N; Matsubara K; Saima S; Ogata H; Ihara H; Nagai T; Matsubara T
    Am J Med Genet A; 2020 Apr; 182(4):659-663. PubMed ID: 32011826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Very young children with Prader-Willi syndrome are refractory to growth hormone-associated decreases in free thyroxine levels.
    Konishi A; Koizumi M; Etani Y; Ida S; Kawai M
    Endocr J; 2023 May; 70(5):501-509. PubMed ID: 36724997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in serum thyroid hormones levels and their mechanisms during long-term growth hormone (GH) replacement therapy in GH deficient children.
    Portes ES; Oliveira JH; MacCagnan P; Abucham J
    Clin Endocrinol (Oxf); 2000 Aug; 53(2):183-9. PubMed ID: 10931099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment.
    Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Van Alfen AA; Van Leeuwen M; Van Wieringen H; Wegdam-den Boer ME; Zwaveling-Soonawala N; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1609-18. PubMed ID: 25668198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
    Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
    Whitman BY; Myers S; Carrel A; Allen D
    Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment.
    Feigerlová E; Diene G; Oliver I; Gennero I; Salles JP; Arnaud C; Tauber M
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of growth hormone (GH) deficiency in previously GH-treated young adults with Prader-Willi syndrome.
    Donze SH; Damen L; van Alfen-van der Velden JAEM; Bocca G; Finken MJJ; Hoorweg-Nijman GJG; Jira PE; van Leeuwen M; Hokken-Koelega ACS
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):118-123. PubMed ID: 30973645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive functioning in children with Prader-Willi syndrome during 8 years of growth hormone treatment.
    Donze SH; Damen L; Mahabier EF; Hokken-Koelega ACS
    Eur J Endocrinol; 2020 Apr; 182(4):405-411. PubMed ID: 31961800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of thyroid function with genetic subtypes and treatment with growth hormone in Prader-Willi syndrome.
    Schmok T; Surampalli A; Khare M; Zandihaghighi S; Baghbaninogourani R; Patolia B; Gold JA; Naidu A; Cassidy SB; Kimonis VE
    Am J Med Genet A; 2024 Jun; ():e63724. PubMed ID: 38837660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid function in patients with Prader-Willi syndrome: an Italian multicenter study of 339 patients.
    Iughetti L; Vivi G; Balsamo A; Corrias A; Crinò A; Delvecchio M; Gargantini L; Greggio NA; Grugni G; Hladnik U; Pilotta A; Ragusa L; Salvatoni A; Wasniewska M; Weber G; Predieri B
    J Pediatr Endocrinol Metab; 2019 Feb; 32(2):159-165. PubMed ID: 30703060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
    de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial.
    Bakker NE; Siemensma EP; Koopman C; Hokken-Koelega AC
    Horm Res Paediatr; 2015; 83(5):321-31. PubMed ID: 25764996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of recombinant growth hormone therapy on thyroid hormone concentrations.
    Kalina-Faska B; Kalina M; Koehler B
    Int J Clin Pharmacol Ther; 2004 Jan; 42(1):30-4. PubMed ID: 14756384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating insulin-like growth factor 1 levels are reduced in very young children with Prader-Willi syndrome independent of anthropometric parameters and nutritional status.
    Koizumi M; Konishi A; Etani Y; Ida S; Kawai M
    Clin Endocrinol (Oxf); 2022 Mar; 96(3):346-352. PubMed ID: 34750859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis.
    Scheermeyer E; Hughes I; Harris M; Ambler G; Crock P; Verge CF; Craig ME; Bergman P; Werther G; van Driel M; Davies PS; Choong CS
    J Paediatr Child Health; 2013 Dec; 49(12):1045-51. PubMed ID: 23781979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.